UFT® plus oral leucovorin calcium (Orzel™) and radiation in combined modality therapy: A comprehensive review Journal Article
| Author: | Minsky, B. D. |
| Article Title: | UFT® plus oral leucovorin calcium (Orzel™) and radiation in combined modality therapy: A comprehensive review |
| Abstract: | 5-fluorouracil (5-FU) has become the most commonly used drug in combination with radiation therapy. The recent availability of oral formulations of 5-FU in conjunction with the ability to modulate the anabolic and catabolic metabolism of 5-FU with leucovorin and dihydropyrimidine dehydrogenase (DPD) inhibitors, respectively, may provide a substantial improvement in the ease of administration and the efficacy of fluoropyrimidine therapy. Several oral fluoropyrimidines are under investigation. UFT (uracil:tegafur) plus oral leucovorin (Orzel™) is the first oral DPD-inhibitory fluoropyrimidine. With daily administration, Orzel achieves similar concentrations of 5-FU obtained with continuous-infusion 5-FU. This paper summarizes the therapeutic rationale for Orzel and reviews the clinical experience with UFT and UFT/LV in combined modality therapy regimens. |
| Keywords: | clinical trial; review; fluorouracil; cancer combination chemotherapy; multimodality cancer therapy; cancer adjuvant therapy; cancer radiotherapy; pancreas cancer; postoperative care; chemotherapy, adjuvant; combined modality therapy; antineoplastic agent; neoplasm; neoplasms; metabolism; lung non small cell cancer; antineoplastic combined chemotherapy protocols; enzyme inhibitor; drug antagonism; head and neck cancer; folinic acid; adjuvant chemotherapy; uterine cervix cancer; malignant neoplastic disease; stomach cancer; preoperative treatment; oxidoreductase; anus cancer; esophagus cancer; administration, oral; folinate calcium; oxidoreductases; 5-fluorouracil; rectum cancer; leucovorin; fluoropyrimidine derivative; clinical trials; oral drug administration; tegafur; uft; uracil; dihydropyrimidine dehydrogenase; humans; human; male; female; priority journal; dihydrouracil dehydrogenase (nadp); dihydropyrimidine dehydrogenase inhibition; orzel; 1 uft protocol; 1-uft protocol |
| Journal Title: | International Journal of Cancer |
| Volume: | 96 |
| Issue: | 1 |
| ISSN: | 0020-7136 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2001-02-20 |
| Start Page: | 1 |
| End Page: | 10 |
| Language: | English |
| DOI: | 10.1002/1097-0215(20010220)96:1<1::aid-ijc1>3.0.co;2-d |
| PUBMED: | 11241325 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 21 May 2015 -- Source: Scopus |
